stockrowScinai Immunotherapeutics Ltd. Sponsored ADR
SCNI Healthcare Biotechnology
Scinai Immunotherapeutics Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 99.2% from fiscal 2024.
- EPS
- −85.8%
- Free cash flow
- +51.1%
Quarter to June 2026, against a year earlier
Follow SCNI
Alert me
Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) P/E ratio
As of 6 November 2026, Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (September 2024) to 200× (October 2020); the current reading is higher than 75% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.1× | (94.14%) |
| FY2024 | 0.9× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.1× | (64.72%) |
| Mar 2025 | 0.2× | (78.48%) |
| Sep 2024 | 0.9× | — |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SPRC SciSparc Ltd. compare | n/m |
| MLEC Moolec Science SA compare | n/m |
| VINC Vincerx Pharma, Inc. compare | n/m |
| VRPX Virpax Pharmaceuticals, Inc. compare | n/m |
| CDT CDT Equity Inc. compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| CERO CERo Therapeutics Holdings, Inc. compare | n/m |
| LNAI Lunai Bioworks Inc. compare | n/m |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR | 0.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)